CSIMarket
 


Chimerix Inc   (CMRX)
Other Ticker:  
 

Chimerix Inc 's Leverage Ratio

CMRX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 16.29%, Leverage Ratio fell to 0.1, below the Chimerix Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 16 other companies have achieved lower Leverage Ratio than Chimerix Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 72, from total ranking in the third quarter 2023 at 79 .

Explain Leverage Ratio?
Who are CMRX Customers?
What are CMRX´s Total Liabilities?


CMRX Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -24.85 % -23.96 % 702.46 % 402.76 % 276.34 %
Y / Y Total Liabilities Change -12.18 % -14.8 % -33.79 % 2.84 % -30.36 %
Leverage Ratio MRQ 0.1 0.08 0.08 0.08 0.09
CMRX's Total Ranking # 72 # 79 # 96 # 27 # 54
Seq. Equity Change -7.33 % -7.05 % -6.74 % -6.44 % -6.24 %
Seq. Total Liabilities Change 16.29 % 0.04 % -6.85 % -18.96 % 12.83 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 27
Overall Market # 72


Leverage Ratio Statistics
High Average Low
0.92 0.12 0.03
(Jun 30 2022)   (Jun 30 2017)




Financial Statements
Chimerix Inc 's Equity $ 193 Millions Visit CMRX's Balance sheet
Chimerix Inc 's Total Liabilities $ 20 Millions Visit CMRX's Balance sheet
Source of CMRX's Sales Visit CMRX's Sales by Geography


Cumulative Chimerix Inc 's Leverage Ratio

CMRX's Leverage Ratio for the trailling 12 Months

CMRX Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -24.85 % -23.96 % 702.46 % 402.76 % 276.34 %
Y / Y Total Liabilities TTM Growth -12.18 % -14.8 % -33.79 % 2.84 % -30.36 %
Leverage Ratio TTM 0.08 0.08 0.08 0.11 0.14
Total Ranking TTM # 5 # 20 # 113 # 2 # 120
Seq. Equity TTM Growth -7.33 % -7.05 % -6.74 % -6.44 % -6.24 %
Seq. Total Liabilities TTM Growth 16.29 % 0.04 % -6.85 % -18.96 % 12.83 %


On the trailing twelve months basis Despite of the net new borrowings of 16.29% during the twelve months period ending in IV Quarter 2023 Chimerix Inc has managed to unchanged Leverage Ratio in the IV Quarter 2023 to 0.08, below Chimerix Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry CMRX recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 5, from total ranking in previous 12 month period at 20.

Explain Leverage Ratio?
Who are CMRX Customers?
What are CMRX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 5


trailing twelve months Leverage Ratio Statistics
High Average Low
0.42 0.1 0.03
(Jun 30 2022)   (Jun 30 2017)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Deciphera Pharmaceuticals Inc   0.28 $ 96.771  Millions$ 350.916  Millions
Abcellera Biologics Inc   0.27 $ 316.818  Millions$ 1,152.318  Millions
Precigen Inc   0.27 $ 32.545  Millions$ 118.498  Millions
Praxis Precision Medicines Inc   0.26 $ 18.279  Millions$ 69.669  Millions
Zentalis Pharmaceuticals Inc   0.26 $ 114.404  Millions$ 437.391  Millions
Aadi Bioscience Inc   0.26 $ 27.228  Millions$ 105.195  Millions
Avidity Biosciences Inc   0.26 $ 127.791  Millions$ 500.764  Millions
Aclaris Therapeutics Inc   0.25 $ 39.800  Millions$ 157.179  Millions
Zymeworks Inc   0.25 $ 116.074  Millions$ 464.806  Millions
Procyon Corporation  0.25 $ 0.583  Millions$ 2.352  Millions
Prothena Corporation Public Limited Company  0.24 $ 135.017  Millions$ 561.365  Millions
Aurinia Pharmaceuticals Inc   0.23 $ 88.099  Millions$ 377.954  Millions
Intra cellular Therapies Inc   0.23 $ 136.871  Millions$ 591.424  Millions
Igc Pharma Inc   0.23 $ 2.091  Millions$ 9.053  Millions
Corcept Therapeutics Inc  0.23 $ 114.812  Millions$ 506.705  Millions
Verona Pharma Plc  0.22 $ 55.886  Millions$ 249.283  Millions
Regeneron Pharmaceuticals Inc   0.22 $ 5,801.500  Millions$ 25,973.100  Millions
Compass Pathways Plc  0.22 $ 50.243  Millions$ 225.744  Millions
Indaptus Therapeutics Inc   0.22 $ 2.672  Millions$ 12.076  Millions
Marker Therapeutics inc   0.22 $ 3.075  Millions$ 14.053  Millions
Sanofi  0.22 $ 18,148.480  Millions$ 83,275.360  Millions
Catalyst Pharmaceuticals Inc   0.21 $ 82.233  Millions$ 387.881  Millions
Aprea Therapeutics Inc   0.21 $ 3.510  Millions$ 16.954  Millions
Leap Therapeutics inc   0.21 $ 12.422  Millions$ 60.141  Millions
Kiniksa Pharmaceuticals ltd   0.20 $ 87.483  Millions$ 438.839  Millions
Tharimmune Inc   0.20 $ 1.815  Millions$ 9.131  Millions
Neurogene Inc   0.20 $ 36.549  Millions$ 186.024  Millions
United Therapeutics Corporation  0.19 $ 1,146.800  Millions$ 5,984.800  Millions
Siga Technologies Inc  0.19 $ 36.705  Millions$ 196.859  Millions
Roivant Sciences Ltd   0.19 $ 1,222.916  Millions$ 6,584.582  Millions

Date modified: 2024-03-01T04:59:42+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com